Comparison the effects of Docetaxe and Irinotecan combined with Xeloda in treatment of end stage gastric cancer
- VernacularTitle:希罗达联合多西他赛或伊立替康治疗晚期胃癌的临床对照研究
- Author:
Ming GAO
;
Fangfang CHANG
;
Yun ZHOU
- Publication Type:Journal Article
- Keywords:
End stage Gastric Cancer;
Docetaxe;
Irinotecan;
Xeloda
- From:
Clinical Medicine of China
2008;24(9):938-940
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the short-term effect of Docetaxe and Irinotecan combined with Xeloda in treatment of end stage gastric cancer.Methods 65 patients with advanced gastric cancer were randomly divided into two groups.33 patients in group A received Docetaxe plus Xeloda and 32 patients in group B received Irinotecan plus Xeloda.At least two treatment cycles were completed.Results The overall response rate is 54.54%(A) and 53.13%(B),and the median progression-free survival was 6.1 months and 6.2 months.Patients in group A experienced more anemia,and patients in group B,diarrhoea.Conclusion The effects of Docetaxe or Irinotecan combined with Xeloda in the treatment of advanced gastric cancer are comparable and well tolerated.
